Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Neurosciences

Neither a doctor nor a teaching hospital

Research payments

$514,703

17 payments

Through program year 2025, Center for Neurosciences is reported as receiving $514,703 in research payments, across 17 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $78,840 3
2024 Research $36,924 4
2021 Research $18,933 1
2020 Research $24,359 2
2019 Research $355,647 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $354,237 6 payments
  2. E.R. Squibb & Sons, L.L.C. $99,356 3 payments
  3. Biogen, Inc. $46,841 3 payments
  4. SK Life Science, Inc. $11,600 3 payments
  5. Kadmon Corporation LLC $2,669 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $306,223 2 payments
  2. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $74,032 2 payments
  3. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $39,884 3 payments
  4. A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities $25,986 1 payment
  5. Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $25,324 1 payment
  6. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $16,047 1 payment
  7. A 12 Month Prospective Multicenter Two Cohort Nonrandomized Open Label Study in Adult Patients With Relapsing Multiple Sclerosis RMS to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 05Mg Fingolimod Fluent $8,130 1 payment
  8. Ykp3089c025 $8,000 2 payments
  9. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $4,808 1 payment
  10. Ykp3089c025 $3,600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record